Stéphanie Le Bas-Bernardet

Stéphanie Le Bas-Bernardet

Auto-generated profile, based on publicly available information

Stéphanie Le Bas-Bernardet

Center for Research in Transplantation and Translational Immunology, Nantes Université, CHU Nantes, INSERM, UMR 1064, Nantes, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LSLinda Scobie
Linda Scobie
VPVered Padler-Karavani
Vered Padler-Karavani
SBStephanie Le Bas-Bernardet
Stephanie Le Bas-Bernardet
CCClaire Crossan
Claire Crossan
JBJosef Blaha
Josef Blaha
JSJean-Paul Soulillou
Jean-Paul Soulillou
Acellular materials of xenogenic origin are used worldwide as xenografts, and phase I trials of viable pig pancreatic islets are currently being performed. However, limited information is available on transmission of porcine endogenous retrovirus (PERV) after xenotransplantation and on the long-term immune response of recipients to xenoantigens. We analyzed the blood of burn patients who had received living pig-skin dressings for up to 8 wk for the presence of PERV as well as for the level and nature of their long term (maximum, 34 y) immune response against pig Ags. Although no evidence of PERV genomic material or anti-PERV Ab response was found, we observed a moderate increase in anti-αGal Abs and a high and sustained anti–non-αGal IgG response in those patients. Abs against the nonhuman sialic acid Neu5Gc constituted the anti–non-αGal response with the recognition pattern on a sialoglycan array differing from that of burn patients treated without pig skin. These data suggest that anti-Neu5Gc Abs represent a barrier for long-term acceptance of porcine xenografts. Because anti-Neu5Gc Abs can promote chronic inflammation, the long-term safety of living and acellular pig tissue implants in recipients warrants further evaluation.

1 February 2003 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SBStéphanie Le Bas-Bernardet
Stéphanie Le Bas-Bernardet
MHMaryvonne Hourmant
Maryvonne Hourmant
SCStéphanie Coupel
Stéphanie Coupel
JBJean-Denis Bignon
Jean-Denis Bignon
JSJean-Paul Soulillou
Jean-Paul Soulillou
Beatrice CharreauBeatrice Charreau
Beatrice Charreau
The vascular endothelium of transplanted organs represents an important target for allograft-directed immune responses. Although HLA antigens expressed on graft endothelial cells (EC) can become tar...

8 December 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
NPN. Poirier
N. Poirier
NDN. Dilek
N. Dilek
CMC. Mary
C. Mary
SVS. Ville
S. Ville
FCF. Coulon
F. Coulon
GBG. Blancho
G. Blancho
Selective targeting of CD28 might represent an effective immunomodulation strategy by preventing T cell costimulation, while favoring coinhibition since inhibitory signals transmitted through CTLA‐4; PD‐L1 and B7 would not be affected. We previously showed in vitro and in vivo that anti‐CD28 antagonists suppress effector T cells while enhancing regulatory T cell (Treg) suppression and immune tolerance. Here, we evaluate FR104, a novel antagonist pegylated anti‐CD28 Fab' antibody fragment, in nonhuman primate renal allotransplantation. FR104, in association with low doses of tacrolimus or with rapamycin in a steroid‐free therapy, prevents acute rejection and alloantibody development and prolongs allograft survival. However, when FR104 was associated with mycophenolate mofetil and steroids, half of the recipients rejected their grafts prematurely. Finally, we observed an accumulation of Helios‐negative Tregs in the blood and within the graft after FR104 therapy, confirmed by Treg‐specific demethylated region DNA analysis. In conclusion, FR104 reinforces immunosuppression in calcineurin inhibitor (CNI)‐low or CNI‐free protocols, without the need of steroids. Accumulation of intragraft Tregs suggested the promotion of immunoregulatory mechanisms. Selective CD28 antagonists might become an alternative CNI‐sparing strategy to B7 antagonists for kidney transplant recipients.

27 February 2003 in Transplantation
Verified
Journal Article
Closed access
SBStéphanie Le Bas-Bernardet
Stéphanie Le Bas-Bernardet
MHMaryvonne Hourmant
Maryvonne Hourmant
NVNathalie Valentin
Nathalie Valentin
CPCatherine Paitier
Catherine Paitier
MGMagali Giral-Classe
Magali Giral-Classe
JBJean-Denis Bignon
Jean-Denis Bignon
The significance of a positive B-cell crossmatch (BCM) in kidney transplantation has always been controversial in the evaluation of its implications on graft survival and specificity of the antibodies involved. We have investigated the sera of 62 recipients of a kidney allograft transplanted across a positive BCM (T negative) for the presence of autoantibodies and anti-human leukocyte antigen (HLA) class I and II antibodies, using a combination of lymphocytotoxicity, enzyme-linked immunosorbent assay (ELISA), and flow cytometry tests. The controls were the 930 patients transplanted over the same period of time with a negative T and BCM. Autoantibodies were detected in 16%, and donor specific anti-HLA class II antibodies, mainly DQ, in 23% of the patients. None had antibodies against donor HLA class I. The target of the antibodies was not identified in 61%. Graft survival was comparable in the controls and in the +BCM patients, with nondonor-specific HLA reactivity. Patients with donor-specific anti-HLA class II antibodies had lower early graft survival and a higher incidence of vascular rejection. However, long-term allograft survival was similar to that of the other groups. These data suggest that in 77% of the patients, BCM positivity was not related with anti-HLA antibodies, and, in this case, graft survival was similar to that of the −BCM controls. In a minority of patients, anti-HLA class II antibodies were responsible for the +BCM, and their presence was associated with lower early, but not long-term, graft survival. Consequently, a +BCM should not systematically contraindicate kidney transplantation.

1 July 2010 in Kidney International
Verified
Journal Article
Closed access
XTXavier Tillou
Xavier Tillou
NPNicolas Poirier
Nicolas Poirier
SBStéphanie Le Bas-Bernardet
Stéphanie Le Bas-Bernardet
JHJeremy Hervouet
Jeremy Hervouet
DMDavid Minault
David Minault
GBGilles Blancho
Gilles Blancho

19 October 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VGVanessa Gauttier
Vanessa Gauttier
SPSabrina Pengam
Sabrina Pengam
JDJustine Durand
Justine Durand
KBKevin Biteau
Kevin Biteau
CMCaroline Mary
Caroline Mary
Nicolas PoirierNicolas Poirier
Nicolas Poirier
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed in preclinical models, the therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, in humans remains unknown. We report a potent synergy between selective SIRPα blockade and ICB in increasing memory T cell responses and reverting exclusion in syngeneic and orthotopic tumor models. Selective SIRPα blockade stimulated tumor nest T cell recruitment by restoring murine and human macrophage chemokine secretion and increased anti-tumor T cell responses by promoting tumor-antigen crosspresentation by dendritic cells. However, nonselective SIRPα/SIRPγ blockade targeting CD47 impaired human T cell activation, proliferation, and endothelial transmigration. Selective SIRPα inhibition opens an attractive avenue to overcoming ICB resistance in patients with elevated myeloid cell infiltration in solid tumors.